相似文献
1
Molecular basis of juvenile myelomonocytic leukemia.
Haematologica. 2010 Feb;95(2):179-82. doi: 10.3324/haematol.2009.016865.
2
[Myelodysplastic syndrome in children].
Rinsho Ketsueki. 2009 Oct;50(10):1560-9.
3
Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia.
Ann Hematol. 2012 Apr;91(4):511-7. doi: 10.1007/s00277-011-1326-9. Epub 2011 Sep 8.
4
CBL mutations in juvenile myelomonocytic leukemia and pediatric myelodysplastic syndrome.
Leukemia. 2010 May;24(5):1090-2. doi: 10.1038/leu.2010.49. Epub 2010 Apr 1.
5
After 95 years, it's time to eRASe JMML.
Blood Rev. 2020 Sep;43:100652. doi: 10.1016/j.blre.2020.100652. Epub 2020 Jan 16.
6
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Pediatr Res. 2009 Mar;65(3):334-40. doi: 10.1203/PDR.0b013e3181961d2a.
7
Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia.
Pediatr Blood Cancer. 2010 Jan;54(1):173-5. doi: 10.1002/pbc.22297.
8
Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.
Leuk Res. 2009 Mar;33(3):355-62. doi: 10.1016/j.leukres.2008.08.022. Epub 2008 Oct 26.
9
Germline mutation of CBL is associated with moyamoya disease in a child with juvenile myelomonocytic leukemia and Noonan syndrome-like disorder.
Pediatr Blood Cancer. 2015 Mar;62(3):542-4. doi: 10.1002/pbc.25271. Epub 2014 Oct 4.
10
Neurofibromatosis type 1 diagnosed in a child based on multiple juvenile xanthogranulomas and juvenile myelomonocytic leukemia.
Pediatr Dermatol. 2015 Jan-Feb;32(1):e29-32. doi: 10.1111/pde.12478. Epub 2014 Dec 16.
引用本文的文献
1
Decitabine-based treatment strategy improved the outcome of HSCT in JMML: a retrospective cohort study.
Front Immunol. 2024 Aug 26;15:1426640. doi: 10.3389/fimmu.2024.1426640. eCollection 2024.
2
Epigenetic Profiling of Mutant JMML Hematopoietic Stem and Progenitor Cells Reveals an Aberrant Histone Landscape.
Cancers (Basel). 2023 Oct 29;15(21):5204. doi: 10.3390/cancers15215204.
3
Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases.
NPJ Syst Biol Appl. 2023 Sep 9;9(1):41. doi: 10.1038/s41540-023-00303-7.
4
Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
Mol Ther. 2023 Apr 5;31(4):986-1001. doi: 10.1016/j.ymthe.2023.01.030. Epub 2023 Feb 3.
5
Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor cells.
Mol Ther. 2022 Jul 6;30(7):2505-2521. doi: 10.1016/j.ymthe.2022.04.009. Epub 2022 Apr 20.
6
Physiological and Aberrant γ-Globin Transcription During Development.
Front Cell Dev Biol. 2021 Apr 1;9:640060. doi: 10.3389/fcell.2021.640060. eCollection 2021.
7
Pediatric Neoplasms Presenting with Monocytosis.
Curr Hematol Malig Rep. 2021 Jun;16(3):235-246. doi: 10.1007/s11899-021-00611-x. Epub 2021 Feb 25.
8
Cleaning up the environment in juvenile myelomonocytic leukemia.
Transl Cancer Res. 2017 Feb;6(Suppl 1):S36-S38. doi: 10.21037/tcr.2017.02.06.
9
[Advances in the treatment of juvenile myelomonocytic leukemia].
Zhongguo Dang Dai Er Ke Za Zhi. 2018 Nov;20(11):958-963. doi: 10.7499/j.issn.1008-8830.2018.11.016.
10
Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.
J Clin Invest. 2018 Dec 3;128(12):5383-5398. doi: 10.1172/JCI121366. Epub 2018 Oct 29.
本文引用的文献
1
Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1.
Haematologica. 2010 Feb;95(2):320-3. doi: 10.3324/haematol.2009.010355. Epub 2009 Dec 16.
2
Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.
Blood. 2009 Aug 27;114(9):1859-63. doi: 10.1182/blood-2009-01-198416. Epub 2009 Jul 1.
3
Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7.
Blood. 2009 Mar 19;113(12):2867-8. doi: 10.1182/blood-2008-12-195693.
4
PTEN deficiency is a common defect in juvenile myelomonocytic leukemia.
Leuk Res. 2009 May;33(5):671-7. doi: 10.1016/j.leukres.2008.09.036. Epub 2008 Nov 17.
5
Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.
Leuk Res. 2009 Mar;33(3):355-62. doi: 10.1016/j.leukres.2008.08.022. Epub 2008 Oct 26.
6
Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.
Cancer Cell. 2008 Oct 7;14(4):335-43. doi: 10.1016/j.ccr.2008.08.014.
7
RAS pathway mutations in juvenile myelomonocytic leukemia.
Acta Haematol. 2008;119(4):207-11. doi: 10.1159/000140632. Epub 2008 Jun 20.
8
Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis.
Blood. 2008 Apr 15;111(8):4322-8. doi: 10.1182/blood-2007-06-095075. Epub 2008 Jan 2.
9
Mutation analysis of the BRAF oncogene in juvenile myelomonocytic leukemia.
Haematologica. 2007 Nov;92(11):1574-5. doi: 10.3324/haematol.11493.
10
Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia.
Haematologica. 2007 Nov;92(11):1557-60. doi: 10.3324/haematol.11201.
Zotero 插件